Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the proportion of patients with virological failure after 48 weeks of treatment
with the combination of efavirenz 600 mg + lamivudine (3TC) 300 mg + abacavir 600 mg once
daily as an antiretroviral simplification regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Germans Trias i Pujol Hospital
Collaborators:
Fundacio Lluita Contra la SIDA Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia